Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0MV3Q
|
|||
| Former ID |
DCL000711
|
|||
| Drug Name |
Axovan-3
|
|||
| Indication | Eating disorder [ICD-11: 6B82] | Discontinued in Phase 1 | [1] | |
| Obesity [ICD-11: 5B81; ICD-10: E66] | Discontinued in Phase 1 | [1] | ||
| Company |
Axovan AG
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neuropeptide Y receptor type 5 (NPY5R) | Target Info | Antagonist | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.